Adlai Nortye (ANL) Competitors

$11.92 +0.36 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$11.87 -0.05 (-0.42%)

As of 04:10 PM Eastern

ANL vs. MLYS, HCM, TRVI, PHVS, and TYRA

Should you buy Adlai Nortye stock or one of its competitors? MarketBeat compares Adlai Nortye with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adlai Nortye include Mineralys Therapeutics (MLYS), HUTCHMED (HCM), Trevi Therapeutics (TRVI), Pharvaris (PHVS), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

How does Adlai Nortye compare to Mineralys Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Adlai Nortye currently has a consensus target price of $21.67, suggesting a potential upside of 81.77%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 65.27%. Given Adlai Nortye's higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Adlai Nortye has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Adlai Nortye's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Mineralys Therapeutics	N/A	-27.92%	-26.98%

In the previous week, Mineralys Therapeutics had 6 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 2 mentions for Adlai Nortye. Mineralys Therapeutics' average media sentiment score of 0.98 beat Adlai Nortye's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Mineralys Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Adlai Nortye and Mineralys Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to HUTCHMED?

Adlai Nortye (NASDAQ:ANL) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Adlai Nortye has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Adlai Nortye presently has a consensus target price of $21.67, indicating a potential upside of 81.77%. HUTCHMED has a consensus target price of $16.88, indicating a potential upside of 40.74%. Given Adlai Nortye's stronger consensus rating and higher probable upside, equities analysts clearly believe Adlai Nortye is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HUTCHMED has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A
HUTCHMED	$548.51M	3.81	$456.91M	N/A	N/A

In the previous week, HUTCHMED had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for HUTCHMED and 2 mentions for Adlai Nortye. HUTCHMED's average media sentiment score of 0.20 beat Adlai Nortye's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
HUTCHMED	N/A	N/A	N/A

Summary

Adlai Nortye and HUTCHMED tied by winning 6 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Adlai Nortye (NASDAQ:ANL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Trevi Therapeutics presently has a consensus target price of $22.90, indicating a potential upside of 62.07%. Adlai Nortye has a consensus target price of $21.67, indicating a potential upside of 81.77%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Trevi Therapeutics and 2 mentions for Adlai Nortye. Trevi Therapeutics' average media sentiment score of 0.00 equaled Adlai Nortye'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Adlai Nortye	N/A	N/A	N/A

Adlai Nortye has higher revenue and earnings than Trevi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A

Summary

Trevi Therapeutics and Adlai Nortye tied by winning 6 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Pharvaris?

Adlai Nortye (NASDAQ:ANL) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Adlai Nortye has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.34, meaning that its share price is 334% less volatile than the broader market.

Adlai Nortye has higher revenue and earnings than Pharvaris.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Pharvaris had 14 more articles in the media than Adlai Nortye. MarketBeat recorded 16 mentions for Pharvaris and 2 mentions for Adlai Nortye. Pharvaris' average media sentiment score of 0.51 beat Adlai Nortye's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye presently has a consensus target price of $21.67, suggesting a potential upside of 81.77%. Pharvaris has a consensus target price of $49.18, suggesting a potential upside of 65.71%. Given Adlai Nortye's higher possible upside, research analysts clearly believe Adlai Nortye is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Adlai Nortye's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Pharvaris	N/A	-67.56%	-61.13%

Summary

Adlai Nortye beats Pharvaris on 7 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Tyra Biosciences presently has a consensus target price of $46.50, suggesting a potential upside of 43.21%. Adlai Nortye has a consensus target price of $21.67, suggesting a potential upside of 81.77%. Given Adlai Nortye's higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tyra Biosciences had 12 more articles in the media than Adlai Nortye. MarketBeat recorded 14 mentions for Tyra Biosciences and 2 mentions for Adlai Nortye. Tyra Biosciences' average media sentiment score of 0.19 beat Adlai Nortye's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye has higher revenue and earnings than Tyra Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Adlai Nortye	$5M	95.36	-$35.53M	N/A	N/A

Adlai Nortye's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Adlai Nortye	N/A	N/A	N/A

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tyra Biosciences has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Summary

Tyra Biosciences beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$476.80M	$3.37B	$6.40B	$12.30B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	N/A	18.95	21.02	25.64
Price / Sales	95.36	296.33	579.61	98.62
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	-56.76	6.93	10.08	7.03
Net Income	-$35.53M	$24.45M	$3.56B	$335.38M
7 Day Performance	-11.77%	3.38%	4.80%	2.62%
1 Month Performance	-26.10%	-0.63%	1.43%	1.37%
1 Year Performance	574.97%	62.03%	36.01%	35.43%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	1.8289 of 5 stars	$11.92 +3.1%	$21.67 +81.8%	+521.5%	$476.80M	$5M	N/A	127
MLYS Mineralys Therapeutics	4.1435 of 5 stars	$26.86 -8.2%	$49.14 +83.0%	+81.5%	$2.22B	N/A	N/A	28
HCM HUTCHMED	3.7963 of 5 stars	$12.67 flat	$16.88 +33.2%	-8.9%	$2.21B	$548.51M	N/A	1,796	News Coverage Positive News
TRVI Trevi Therapeutics	2.9728 of 5 stars	$15.27 +3.5%	$22.90 +50.0%	+129.1%	$2.17B	N/A	N/A	20	Analyst Forecast
PHVS Pharvaris	3.937 of 5 stars	$32.94 +5.4%	$47.17 +43.2%	+86.2%	$2.15B	N/A	N/A	30	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. MLYS, HCM, TRVI, PHVS, and TYRA

How does Adlai Nortye compare to Mineralys Therapeutics?

Summary

How does Adlai Nortye compare to HUTCHMED?

Summary

How does Adlai Nortye compare to Trevi Therapeutics?

Summary

How does Adlai Nortye compare to Pharvaris?

Summary

How does Adlai Nortye compare to Tyra Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. MLYS, HCM, TRVI, PHVS, and TYRA

How does Adlai Nortye compare to Mineralys Therapeutics?

Do analysts recommend ANL or MLYS?

Which has more volatility and risk, ANL or MLYS?

Is ANL or MLYS more profitable?

Does the media favor ANL or MLYS?

Which has better earnings and valuation, ANL or MLYS?

Do institutionals & insiders have more ownership in ANL or MLYS?

Summary

How does Adlai Nortye compare to HUTCHMED?

Which has more volatility & risk, ANL or HCM?

Do analysts rate ANL or HCM?

Do institutionals & insiders hold more shares of ANL or HCM?

Which has preferable valuation & earnings, ANL or HCM?

Does the media favor ANL or HCM?

Is ANL or HCM more profitable?

Summary

How does Adlai Nortye compare to Trevi Therapeutics?

Do analysts rate TRVI or ANL?

Do insiders and institutionals believe in TRVI or ANL?

Which has more volatility and risk, TRVI or ANL?

Does the media prefer TRVI or ANL?

Is TRVI or ANL more profitable?

Which has preferable earnings & valuation, TRVI or ANL?

Summary

How does Adlai Nortye compare to Pharvaris?

Which has more risk & volatility, ANL or PHVS?

Which has preferable earnings and valuation, ANL or PHVS?

Do institutionals & insiders hold more shares of ANL or PHVS?

Does the media favor ANL or PHVS?

Do analysts recommend ANL or PHVS?

Is ANL or PHVS more profitable?

Summary

How does Adlai Nortye compare to Tyra Biosciences?

Do analysts prefer TYRA or ANL?

Does the media favor TYRA or ANL?

Which has stronger earnings and valuation, TYRA or ANL?

Is TYRA or ANL more profitable?

Do insiders and institutionals hold more shares of TYRA or ANL?

Which has more volatility & risk, TYRA or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools